Efficacy and Safety of Peginterferon Alfa-2a (40 KD) in Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment With Nucleoside (Nucleotide) Analogues - an Observational Study in Real-life Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 23 Jan 2014
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 23 Jan 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 17 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.